BioSpace News Archive

- Enrollment Complete in the Phase 3 DeFi Trial of Nirogacestat in Adult Patients with Desmoid Tumors - - Clinical Collaborations Signed with Janssen, Pfizer and Precision Biosciences to Evaluate Nirogacestat in Combination with BCMA-Directed Therapies Across Modalities for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma - - Entered into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center

Acquisition of Handl Therapeutics BV augments UCB’s existing early gene therapy pipeline with two research programs, a proprietary adeno-associated virus (AAV) capsid technology platform and capabilities

Q3/2020 net revenues of approximately $21 million, with gross profit of $10.6 million, or approximately 51%, up from $6.7 million and approximately 32% in Q2/2020

Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, has announced a license and commercialization agreement with Aspen Pharma USA Inc. and Aspen Global Incorporated, both wholly owned subsidiaries of Aspen Pharmacare Holdings Limited, for the exclusive rights to relaunch Cenestin ® (synthetic conjugated estrogen

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced its recent accomplishments and financial results for the quarter ended September 30, 2020.

Strong pipeline progress amid challenging COVID-19 environment Oral presentation of MAD1 results at upcoming 2020 ASH Virtual Annual Meeting from the randomized, placebo-controlled multi-center Phase 1 trial evaluating FT-4202 in people with sickle cell disease MAD2 cohort of the Phase 1 trial now enrolling with 600 mg dose

Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter and nine months ended September 30, 2020 and provided an update on corporate progress. “Exicure has seen growth and clinical and pre-clinical advancement during the third quarter of this year,” said Dr. David Giljo

Organicell Provides Update on Its COVID-19 Clinical Trial Using Zofin TM Anticipates Phase I/II trial completion by end of year Anticipates Phase IIb trial to begin in Q1 2021 Seeks to retain a global contract research organization (“CRO”)

BIONIK Laboratories Corp . (OTCQB: BNKL) , a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for its second quarter of fiscal year 2021, ending September 30, 2020. Financial highlights for the second quarter of fiscal 2021 and recent weeks include:

Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will participate in fireside chats at the Stifel and Jefferies 2020 Virtual Healthcare Conferences. Details for the presentations are as follows: The Stifel 2020 Virtual Healthcare Conferen